For over a decade, pharma has failed at omnichannel because it's treated as a separate department. True success requires embedding omnichannel capabilities directly within marketing and sales, not isolating them as an artificial discipline that hinders progress.
As AI tools increasingly guide patient diagnosis and treatment recommendations, pharma's focus must shift. The primary challenge is no longer just influencing the HCP directly, but ensuring your product data is structured to "win" in the AI's algorithmic suggestions.
The technical and data preparation for an AI-driven healthcare world will take pharma companies 18-24 months. If they wait until AI tools are mainstream, they will face an insurmountable two-year gap to catch up, a period in which they will become irrelevant.
Many pharma companies treat mandatory CRM migrations as a simple technical task, a strategic error that locks them into an outdated operating model. This should be a catalyst to redesign commercial processes, not a burden to simply get over with.
While critical, compliance is frequently weaponized as an unchallengeable reason to reject innovation or collaboration between commercial and medical affairs. It's an easy way to shut down conversations about change when the real barrier is a lack of will to evolve.
An incentive model based on flawed geographical sales data forced reps to spend 30% of their time on administrative tasks gathering confirmations from doctors. This highlights how internally-focused metrics can directly sabotage customer engagement and overall commercial success.
The current industry-wide focus on migrating from one monolithic CRM to another is shortsighted. The next evolution is headless architecture, where backend systems become data sources for an intelligent front-end agent that creates UIs and pulls content on the fly.
When sales reps are asked to input data but receive no tangible value in return, they lose trust in the system. A rep openly admitted to answering dishonestly until he saw the data was used constructively, proving data quality is a function of perceived value.
The classic closed-loop model informing annual strategy is obsolete. Advanced analytics enable a "multi-loop" system where insights can immediately change sales rep talking points (execution loop) or marketing journeys (orchestration loop) without waiting for the next strategy cycle.
Instead of relying solely on traditional market research, pharma companies can create synthetic HCP personas or "digital twins" from combined data. These can be used to run simulations, test campaign approaches, predict outcomes, and optimize budgets before real-world execution.
Most pharma content is created from the brand's perspective: "here are our key messages." A truly customer-centric model reverses this. It starts by deeply understanding the HCP's challenges and then builds content showing how the brand helps solve those specific problems.
The industry-wide failure of HCP portal initiatives stems from a fundamental misunderstanding of user needs. Doctors don't want 20 different logins to access purely promotional content that is difficult to navigate. The value proposition is misaligned with the user's desire for unbiased, accessible information.